Tekla Life Sciences Investors Stock News

For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV,

Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth

Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.

HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.

2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve t

For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are g

The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biote

Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.

Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while it

HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend

You can be forgiven if your stomach tightens just a bit when you go to check your retirement account.

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive.

5 Closed-End Funds Bought In November

Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income

BOSTON--(BUSINESS WIRE)--On August 17, 2021, Tekla Life Sciences Investors declared a distribution of $0.43 per share. The record date for the stock distribution is August 27, 2021 and the payable dat